Mark Hillman's BMY Position Overview
Mark Hillman (via Hillman Capital Management, Inc.) currently holds 69.4K shares of Bristol-Myers Squibb Company (BMY) worth $3.13 M, representing 1.82% of the portfolio. First purchased in 2019-Q4, this long-term strategic position has been held for 24 quarters.
Based on 13F filings, Mark Hillman has maintained a strategic position in BMY, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2021, adding 33.1K shares. Largest reduction occurred in Q1 2025, reducing 49.7K shares.
Analysis based on 13F filings available since 2013 Q2
Mark Hillman's Bristol-Myers Squibb Company (BMY) Holding Value Over Time
Track share changes against reported price movement
Quarterly Bristol-Myers Squibb Company (BMY) Trades by Mark Hillman
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2019 | +86,642 | Add 0.00% | 86,641 | $64.18 |
| Q1 2020 | -1,711 | Reduce 1.97% | 84,930 | $55.74 |
| Q2 2020 | -904 | Reduce 1.06% | 84,026 | $58.80 |
| Q3 2020 | -352 | Reduce 0.42% | 83,674 | $60.29 |
| Q4 2020 | +316 | Add 0.38% | 83,990 | $62.03 |
| Q1 2021 | +33,117 | Add 39.43% | 117,107 | $63.13 |
| Q2 2021 | +950 | Add 0.81% | 118,057 | $66.82 |
| Q3 2021 | +20,231 | Add 17.14% | 138,288 | $59.17 |
| Q4 2021 | -4,351 | Reduce 3.15% | 133,937 | $62.35 |
| Q1 2022 | +1,794 | Add 1.34% | 135,731 | $73.03 |
| Q2 2022 | -135,731 | Sold Out | 135,731 | $0.00 |
| Q2 2024 | +160,529 | New Buy | 160,529 | $41.53 |
| Q3 2024 | -84 | Reduce 0.05% | 160,445 | $51.74 |
| Q4 2024 | -45,774 | Reduce 28.53% | 114,671 | $56.56 |
| Q1 2025 | -49,652 | Reduce 43.30% | 65,019 | $60.99 |
| Q2 2025 | +6,796 | Add 10.45% | 71,815 | $46.29 |
| Q3 2025 | -2,375 | Reduce 3.31% | 69,440 | $45.10 |
Mark Hillman's Bristol-Myers Squibb Company Investment FAQs
Mark Hillman first purchased Bristol-Myers Squibb Company (BMY) in Q4 2019, acquiring 86,641 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Mark Hillman has held Bristol-Myers Squibb Company (BMY) for 24 quarters since Q4 2019. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Mark Hillman's largest addition to Bristol-Myers Squibb Company (BMY) was in Q2 2024, adding 160,529 shares worth $6.67 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Mark Hillman's firm, Hillman Capital Management, Inc., owns 69,440 shares of Bristol-Myers Squibb Company (BMY), valued at approximately $3.13 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Bristol-Myers Squibb Company (BMY) represents approximately 1.82% of Mark Hillman's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Mark Hillman's peak holding in Bristol-Myers Squibb Company (BMY) was 160,529 shares, as reported at the end of Q2 2024. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.